Chang-Ik Yoon: Not applicable (device, behavioral) study in Breast Neoplasm Malignant Primary, Lymphedema Arm (264 participants)
Chang-Ik Yoon: Not applicable (device, behavioral) study in Breast Neoplasm Malignant Primary, Lymphedema Arm (264 participants). Its enrollment of 264 is above the median of 80 (81st percentile). Dated 2 days ago, it is inside the fresh trigger window. Score 65/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 264 · 81th percentile of 8,879 ClinicalTrialStartPulse records · 3.3x the median
Free preview: all 14 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Chang-Ik Yoon |
| Sponsor type | Academic and hospital |
| Study | Agentic AI App and Home Bioimpedance Monitoring for Endocrine Therapy Adherence and Lymphedema in Breast Cancer Survivors |
| NCT ID | NCT07911839 |
| Phase | Not applicable (device, behavioral) |
| Status | not yet recruiting |
| Conditions | Breast Neoplasm Malignant Primary; Lymphedema Arm; Medication Adherence; Ductal Carcinoma In Situ |
| Intervention types | behavioral, other, device |
| Target enrollment | 264 |
| Site countries | South Korea |
| Posted | 2026-11-03 |
| Planned start | 2026-10-29 |
| Event | Newly registered study |
| Event date | 2026-11-03 |
| enrollment percentile | 81th of 8,879 (median 80, 3.3x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Chang-Ik Yoon
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Unlock Chang-Ik Yoon + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-11-03
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Chang-Ik Yoon and 6,603 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,603
- Chang-Ik Yoon's enrollment: 81st percentile of 8,879 records
- Timing: High: dated in the last 7 days
- Estimated pipeline if you contact every NONUS peer: $1,320,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
65 / 100 Score
- Posted in the last two weeks.
- 264 participants planned.
- Not yet recruiting: vendors still being chosen.
What is the ClinicalTrialStartPulse record for Chang-Ik Yoon?
Chang-Ik Yoon registered a Not applicable (device, behavioral) study (NCT07911839) in Breast Neoplasm Malignant Primary targeting 264 participants, posted 2026-11-03.
How does Chang-Ik Yoon compare to other ClinicalTrialStartPulse records?
Its enrollment of 264 sits in the upper half (81th percentile) of 8,879 records; the median is 80. It is fresh: dated 2 days ago, inside the window where early outreach matters most.
Chang-Ik Yoon vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Chang-Ik Yoon | NONUS | 264 | 81st | 2026-11-03 |
| Galderma R&D | NONUS | 326 | 84th | 2026-11-02 |
| Galderma R&D | NONUS | 162 | 72nd | 2026-11-03 |
| A.M.I. Agency for Medical Innovations GmbH | NONUS | 100 | 60th | 2026-10-30 |
Related records
ClinicalTrialStartPulse: Not applicable (device, behavioral) ClinicalTrialStartPulse: Outside the US only
How to monitor Chang-Ik Yoon and peer not applicable (device, behavioral) records
Get new ClinicalTrialStartPulse records like Chang-Ik Yoon by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.